Insider Selling: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Sells $27,147.96 in Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIXGet Free Report) insider Christine Ring sold 1,596 shares of the firm’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $17.01, for a total value of $27,147.96. Following the completion of the transaction, the insider now owns 19,838 shares in the company, valued at approximately $337,444.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christine Ring also recently made the following trade(s):

  • On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total value of $6,800.00.

Nurix Therapeutics Stock Up 5.7 %

NASDAQ:NRIX opened at $16.86 on Thursday. Nurix Therapeutics, Inc. has a twelve month low of $4.22 and a twelve month high of $18.12. The stock’s 50 day moving average price is $14.68 and its two-hundred day moving average price is $11.53.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last released its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.04. The business had revenue of $16.59 million during the quarter, compared to the consensus estimate of $14.58 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. Sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on NRIX shares. Wells Fargo & Company decreased their price target on Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Friday, February 16th. Stephens started coverage on Nurix Therapeutics in a report on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price target on the stock. HC Wainwright decreased their price target on Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Morgan Stanley raised their price target on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, May 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.33.

Get Our Latest Stock Report on NRIX

Institutional Trading of Nurix Therapeutics

Several large investors have recently bought and sold shares of NRIX. Redmile Group LLC raised its position in Nurix Therapeutics by 37.7% in the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after purchasing an additional 1,226,497 shares during the last quarter. ARK Investment Management LLC boosted its position in shares of Nurix Therapeutics by 23.2% during the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after buying an additional 601,952 shares during the last quarter. Affinity Asset Advisors LLC boosted its position in shares of Nurix Therapeutics by 176.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock valued at $7,122,000 after buying an additional 440,112 shares during the last quarter. Ikarian Capital LLC purchased a new position in shares of Nurix Therapeutics during the first quarter valued at approximately $4,410,000. Finally, Opaleye Management Inc. bought a new stake in Nurix Therapeutics during the first quarter worth $3,928,000.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More

Insider Buying and Selling by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.